Skip to main content

Table 1 Baseline demographic and clinical characteristics (FAS)

From: Efficacy and safety of peppermint oil for the treatment in Japanese patients with irritable bowel syndrome: a prospective, open-label, and single-arm study

Items

N = 69

(%)

Sex

Male

37

53.6

Female

32

46.4

Age (years)

Mean

37.8

 

SD

11.8

 

Maximum

60

 

Median

39.0

 

Minimum

17

 

< 20

2

2.9

20–29

20

29.0

30–39

14

20.3

40–49

19

27.5

50–59

13

18.8

≥ 60

1

1.4

Weight (kg)

Mean

61.29

 

SD

11.65

 

Maximum

87.0

 

Median

60.00

 

Minimum

39.0

 

< 50

13

18.8

≥ 50– < 60

20

29.0

≥ 60– < 70

21

30.4

≥ 70– < 80

10

14.5

≥ 80

5

7.2

Duration of illness

≥ 6 months– < 1 year

4

5.8

≥ 1 year– < 3 years

13

18.8

≥ 3 years- < 10 years

22

31.9

≥ 10 years

30

43.5

IBS subtypes

IBS-C

18

26.1

IBS-D

35

50.7

IBS-M

16

23.2

Unsubtyped

0

0.0

Pretreatment drugs

No

67

97.1

Yes

2

2.9

Pretreatment therapy

No

69

100.0

Yes

0

0.0

Intake of health food

No

69

100.0

Yes

0

0.0

Organic diseasea

No

56

81.2

Yes

13

18.8

Medical history

No

51

73.9

Yes

18

26.1

Concomitant medicine

No

63

91.3

Yes

6

8.7

Concomitant therapy

No

69

100.0

Yes

0

0.0

  1. SD standard deviation
  2. aDiverticulum of the large intestine or a 5 mm or smaller polyp